Literature DB >> 15588130

Myocardial infarct size-limiting effect of chronic hypoxia persists for five weeks of normoxic recovery.

J Neckár1, B Ostádal, F Kolár.   

Abstract

We examined cardioprotective effect of chronic hypoxia and the time course of its recovery under normoxic conditions. Adult male Wistar rats were exposed to intermittent hypobaric hypoxia (7000 m, 8 h/day, 35 exposures) and susceptibility of their hearts to ischemia-induced ventricular arrhythmias and myocardial infarction was evaluated in anesthetized open-chest animals subjected to 30-min coronary artery occlusion and 4-h reperfusion on the day after the last hypoxic exposure and at 7, 35 and 90 days of normoxic recovery. The infarct size was reduced from 69.2+/-1.7 % of the area at risk in normoxic controls to 48.0+/-2.2 % in the chronically hypoxic group and to 61.6+/-2.3 % in the group recovered for 7 days. This residual protection persisted for at least 35 days of normoxic recovery but it was absent after 90 days. In contrast to the infarct size-limitation, the antiarrhythmic protection disappeared already during the first week; the incidence of ventricular fibrillation was even significantly increased 7 and 90 days after the last hypoxic exposure. In conclusion, the duration of cardioprotection induced by chronic hypoxia differs markedly, depending on the end point of ischemia/reperfusion injury examined. Whereas the increased tolerance to lethal myocardial injury persists for at least 5 weeks after the termination of hypoxia, the antiarrhythmic protection rapidly vanishes, being replaced with transient proarrhythmic effect.

Entities:  

Mesh:

Year:  2004        PMID: 15588130

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  19 in total

1.  Intermittent hypoxia conditioning protects mitochondrial cytochrome c oxidase of rat cerebellum from ethanol withdrawal stress.

Authors:  Xiaohua Ju; Robert T Mallet; H Fred Downey; Daniel B Metzger; Marianna E Jung
Journal:  J Appl Physiol (1985)       Date:  2012-03-08

Review 2.  Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy.

Authors:  Aslan T Turer; Joseph A Hill
Journal:  Am J Cardiol       Date:  2010-08-01       Impact factor: 2.778

Review 3.  The exercising heart at altitude.

Authors:  José A L Calbet; Paul Robach; Carsten Lundby
Journal:  Cell Mol Life Sci       Date:  2009-10-07       Impact factor: 9.261

4.  Differential role of PI3K/Akt pathway in the infarct size limitation and antiarrhythmic protection in the rat heart.

Authors:  Tána Ravingerová; Jana Matejíková; Jan Neckár; Eva Andelová; Frantisek Kolár
Journal:  Mol Cell Biochem       Date:  2006-10-03       Impact factor: 3.396

Review 5.  Therapeutic potential of intermittent hypoxia: a matter of dose.

Authors:  Angela Navarrete-Opazo; Gordon S Mitchell
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-09-17       Impact factor: 3.619

6.  Mitochondrial BKCa channels contribute to protection of cardiomyocytes isolated from chronically hypoxic rats.

Authors:  Gudrun H Borchert; Chengtao Yang; Frantisek Kolár
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-26       Impact factor: 4.733

7.  Obstructive sleep apnea and acute myocardial infarction severity: ischemic preconditioning?

Authors:  Neomi Shah; Susan Redline; H Klar Yaggi; Richard Wu; C George Zhao; Robert Ostfeld; Mark Menegus; Daniel Tracy; Elizabeth Brush; W David Appel; Robert C Kaplan
Journal:  Sleep Breath       Date:  2012-10-23       Impact factor: 2.816

8.  Selection of optimal reference genes for gene expression studies in chronically hypoxic rat heart.

Authors:  Daniel Benak; Dita Sotakova-Kasparova; Jan Neckar; Frantisek Kolar; Marketa Hlavackova
Journal:  Mol Cell Biochem       Date:  2019-07-12       Impact factor: 3.842

Review 9.  Hypoxic Conditioning as a New Therapeutic Modality.

Authors:  Samuel Verges; Samarmar Chacaroun; Diane Godin-Ribuot; Sébastien Baillieul
Journal:  Front Pediatr       Date:  2015-06-22       Impact factor: 3.418

10.  ZFP580, a novel zinc-finger transcription factor, is involved in cardioprotection of intermittent high-altitude hypoxia against myocardial ischemia-reperfusion injury.

Authors:  Xiang-Yan Meng; Hai-Long Yu; Wen-Cheng Zhang; Tian-Hui Wang; Xia Mai; Hong-Tao Liu; Rui-Cheng Xu
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.